TuHURA Biosciences Q2 cash drops to $1 million
- TuHURA Biosciences reported $1 million in cash at June 30, while Q2 R&D spending increased to $6.6 million.
- HURA shares were unchanged at $2.30 in the latest available quote following the announcement.
- The company says its $50 million credit facility should extend its cash runway into 2028 while supporting IFx-2.0, TBS-2025 and MDSC programs.
TuHURA Biosciences (NASDAQ:HURA) ended Q2 2026 with $1 million in cash as R&D spending rose to $6.6 million amid increased clinical activity.
R&D expense increased from $4.9 million a year earlier, while G&A expense rose to $2.1 million from $1.9 million.
TuHURA used $13 million in operating cash during the first half and generated $10.6 million from financing activities, including ATM sales and credit-facility draws.
Following the announcement, TuHURA Biosciences' share price was unchanged at $2.30 in the latest available quote.
TuHURA filed an IND for TBS-2025 in June and says it plans to begin a Phase 1b/2 trial in selected AML patients during the second half of 2026.
The company’s $50 million facility carries 12% annual interest and matures April 21, 2031, while TuHURA says it should provide funding into 2028.
Frequently asked questions
More from United States
Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%
Enerflex Q3 free cash flow rises to $102 million as net earnings climb
WTW Q3 revenue rises 8% to $2.46 billion as AI savings plan advances
